YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation

Carcinogenesis

Volumn 29, Issue 11, 2008, Pages 2139-2146

  Yokoyama, Toshihiko ^a   Osada, Hirotaka ^a,b   Murakami, Hideki ^a   Tatematsu, Yoshio ^a   Taniguchi, Tetsuo ^a   Kondo, Yutaka ^a   Yatabe, Yasushi ^a   Hasegawa, Yoshinori ^c   Shimokata, Kaoru ^d   Horio, Yoshitsugu ^a   Hida, Toyoaki ^a   Sekido, Yoshitaka ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d CHUBU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; MERLIN; PROTEIN KINASE YES; PROTEIN NF2; PROTEIN YAP1; RNA; SERINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL IMMORTALIZATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; GENETIC TRANSFECTION; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; MAMMAL CELL; MESOTHELIUM CELL; MOLECULAR MECHANICS; ONCOGENE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BASE SEQUENCE; CELL PROLIFERATION; CHROMOSOME MAPPING; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 11; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MESOTHELIOMA; NEUROFIBROMIN 2; NUCLEIC ACID CONFORMATION; PHOSPHOPROTEINS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 56049125036     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn200     Document Type: Article

References (50)

1. Carbone,M. et al. (2002) The pathogenesis of mesothelioma. Semin. Oncol., 29, 2-17.
2. Pass,H.I. et al. (2004) Malignant pleural mesothelioma. Curr. Probl. Cancer, 28, 93-174.
3. Robinson,B.W. et al. (2005) Advances in malignant mesothelioma. N. Engl. J. Med., 353, 1591-1603.
4. Ramos-Nino,M.E. et al. (2006) Cellular and molecular parameters of mesothelioma. J. Cell. Biochem., 98, 723-734.
5. Vogelzang,N.J. et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol., 21, 2636-2644.
6. van Meerbeeck,J.P. et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol., 23, 6881-6889.
7. Ascoli,V. et al. (2001) DNA copy number changes in familial malignant mesothelioma. Cancer Genet. Cytogenet., 127, 80-82.
8. Sugarbaker,D.J. et al. (2008) Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc. Natl Acad. Sci. USA, 105, 3521-3526.
9. Ladanyi,M. (2005) Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer, 49 (suppl. 1), S95-S98.
10. Musti,M. et al. (2006) Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet. Cytogenet., 170, 9-15.
11. Pei,J. et al. (2006) High-resolution analysis of 9p loss in human cancer cells using single nucleotide polymorphism-based mapping arrays. Cancer Genet. Cytogenet., 170, 65-68.
12. Sekido,Y. et al. (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res., 55, 1227-1231.
13. Bianchi,A.B. et al. (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl Acad. Sci. USA, 92, 10854-10858.
14. Cheng,J.Q. et al. (1999) Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer, 24, 238-242.
15. Baser,M.E. (2006) The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum. Mutat., 27, 297-306.
16. Sun,C.X. et al. (2002) Protein 4.1 tumor suppressors: Getting a FERM grip on growth regulation. J. Cell Sci., 115, 3991-4000.
17. McClatchey,A.I. et al. (2005) Membrane organization and tumorigenesis - the NF2 tumor suppressor, Merlin. Genes Dev., 19, 2265-2277.
18. Taniguchi,T. et al. (2007) Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci., 98, 438-446.
19. Komuro,A. et al. (2003) WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J. Biol. Chem., 278, 33334-33341.
20. Osada,H. et al. (2005) ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res., 65 10680-10685.
21. Basu,S. et al. (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell, 11, 11-23.
22. Hayashita,Y. et al. (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res., 65, 9628-9632.
23. Heintz,N.H. et al. (1993) Persistent induction of c-fos and c-jun expression by asbestos. Proc. Natl Acad. Sci. USA, 90, 3299-3303.
24. Mariani,O. et al. (2007) JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell, 11, 361-374.
25. Zender,L. et al. (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell, 125, 1253-1267.
26. Overholtzer,M. et al. (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl Acad. Sci. USA, 103, 12405-12410.
27. Huang,J. et al. (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell, 122, 421-434.
28. Mohler,P.J. et al. (1999) Yes-associated protein 65 localizes p62(c-Yes) to the apical compartment of airway epithelia by association with EBP50. J. Cell Biol., 147, 879-890.
29. Murthy,A. et al. (1998) NHE-RF, a regulatory cofactor for Na(+)-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins. J. Biol. Chem., 273, 1273-1276.
30. Bissig,H. et al. (1999) Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am. J. Pathol., 155, 267-274.
31. Imoto,I. et al. (2001) Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res., 61, 6629-6634.
32. Dai,Z. et al. (2003) A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum. Mol. Genet., 12, 791-801.
33. Baldwin,C. et al. (2005) Multiple microalterations detected at high frequency in oral cancer. Cancer Res., 65, 7561-7567.
34. Zanazzi,C. et al. (2007) Gene expression profiling and gene copy-number changes in malignant mesothelioma cell lines. Genes Chromosomes Cancer, 46, 895-908.
35. Hamaratoglu,F. et al. (2006) The tumour-suppressor genes NF2/ Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol., 8, 27-36.
36. Pan,D. (2007) Hippo signaling in organ size control. Genes Dev., 21, 886-897.
37. Zhao,B. et al. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev., 21, 2747-2761.
38. Yagi,R. et al. (1999) A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J., 18, 2551-2562.
39. Vitolo,M.I. et al. (2007) The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biol. Ther., 6, 856-863.
40. Aqeilan,R.I. et al. (2005) WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res., 65, 6764-6772.
41. Vassilev,A. et al. (2001) TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev., 15, 1229-1241.
42. Strano,S. et al. (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J. Biol. Chem., 276, 15164-15173.
43. Strano,S. et al. (2005) The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol. Cell, 18, 447-459.
44. Matallanas,D. et al. (2007) RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol. Cell, 27, 962-975.
45. Xiao,G.H. et al. (2005) The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol. Cell. Biol., 25, 2384-2394.
46. Poulikakos,P.I. et al. (2006) Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene, 25, 5960-5968.
47. Lee,H. et al. (2007) Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol. Cell. Biol., 27, 2103-2119.
48. Fleury-Feith,J. et al. (2003) Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene, 22, 3799-3805.
49. Altomare,D.A. et al. (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res., 65, 8090-8095.
50. Jongsma,J. et al. (2008) A conditional mouse model for malignant mesothelioma. Cancer Cell, 13, 261-271.